Skip to main content
ACR Convergence 2024 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream

  1. Home

  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    SpA Including PsA – Treatment Poster I
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0067: Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
    Abstract Poster Presenter: Shashank Cheemalavagu, MD (he/him/his) – Cleveland Clinic Foundation
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0068: Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
    Abstract Poster Presenter: Yong-Wook Park, MD, PhD – Department of Rheumatology, Chonnam National University Medical School and Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0069: Activation of Cardiovascular Inflammation and Wnt Signaling in Spondyloarthritis: Insights from the HLA-B27 Transgenic Rat Model
    Abstract Poster Presenter: Hansun Song, n/a – College of Medicine, Inha University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0070: Shared and Unique Fecal and Plasma Metabolic Signatures and Increased Inflammatory Markers in Ankylosing Spondylitis, Psoriatic Arthritis and Acute Anterior Uveitis
    Abstract Poster Presenter: Tejpal Gill, PhD – OHSU
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0071: Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis
    Abstract Poster Presenter: Jina Yeo, MD, PhD (she/her/hers) – Gachon University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0072: The Association Between Activation of Inflammasome and HLA-B27 in Dendritic Cells of Patients with Axial Spondyloarthritis
    Abstract Poster Presenter: Jina Yeo, MD, PhD (she/her/hers) – Gachon University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0073: Self or Bacteria-reactive Th17 Expand from Conventional and Regulatory T Cells in Parabacteroides Goldsteinii Gnotobiotic Arthritic SKG Mice, in Context of Interferon-driven Synovial Inflammatory Macrophages and Reduced Bacterial Immune Regulation
    Abstract Poster Presenter: Benjamin Cai, BS (he/him/his) – Frazer Institute, The University of Queensland
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0074: Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
    Abstract Poster Presenter: Maria de la Luz Garcia-Hernandez, PhD (she/her/hers) – University of Rochester
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0075: Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
    Abstract Poster Presenter: Darshini Ganatra, PhD – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0076: Early (3-Month) and Maintained (12-Month) Comparative Effectiveness of 5 Different Classes of Advanced Therapies in a Large Multinational Cohort of Real-World PsA Patients
    Abstract Poster Presenter: Dennis McGonagle, MD,PhD – Uni of Leeds
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0077: Characteristics of Axial Spondyloarthritis in Patients with Onset Chronic Low Back Pain After Age 45
    Abstract Poster Presenter: Fatma Zohra Yasmina Heddi, MD (she/her/hers) – Oran University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0078: Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity
    Abstract Poster Presenter: Archita Srinath, BSc,MSc (she/her/hers) – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0079: Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0080: Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
    Abstract Poster Presenter: KUNHAI TANG, BS – fudan University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0081: The Axial Spondyloarthritis Risk Variant CARD9 S12N Enhances Neutrophil-mediated Th Responses
    Abstract Poster Presenter: Ruth J. Napier, PhD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0082: Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis
    Abstract Poster Presenter: Tom Macleod, PhD – Leeds Institute of Rheumatic and Musculoskeletal Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0083: Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice
    Abstract Poster Presenter: Mariia Korshko, MSc – UHN
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0539: Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association with HLA-B27 in European and Ibero-American Populations: Data from the REGISPONSER and RESPONDIA Registries
    Abstract Poster Presenter: Maria Angeles Puche Larrubia, MD,PhD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0540: Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
    Abstract Poster Presenter: Jose Meade-Aguilar, MD (he/him/his) – Boston University/Boston Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0541: Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
    Abstract Poster Presenter: Clementina Lopez-Medina, MD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0542: Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
    Abstract Poster Presenter: Clementina Lopez-Medina, MD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0543: Impact of Peripheral Manifestations on Function, Health, and Work Productivity in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
    Abstract Poster Presenter: Clementina Lopez-Medina, MD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0544: A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0545: Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
    Abstract Poster Presenter: Stylianos Georgiadis, PhD – Rigshospitalet Glostrup
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0546: Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice
    Abstract Poster Presenter: Nehad Soloman, MD – Arizona Arthritis & Rheumatology Associates, P.C.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0547: EspANDE Project: Improvement of Primary Care-Rheumatology Coordination in Spondyloarthritis in a Health Area in Northern Spain
    Abstract Poster Presenter: Julio Sanchez Martin, MD – Hospital Universitario Marqués de Valdecilla
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0548: Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
    Abstract Poster Presenter: David Kiefer, MD (he/him/his) – Rheumazentrum Ruhrgebiet; Ruhr-Universität Bochum
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0549: Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
    Abstract Poster Presenter: Nelly Ziade, MD, PhD, FRCP – Saint-Joseph University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0550: Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
    Abstract Poster Presenter: Nelly Ziade, MD, PhD, FRCP – Saint-Joseph University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0551: Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study
    Abstract Poster Presenter: Dafne Capelusnik, MD – Tel Aviv Sourasky Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0552: Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study
    Abstract Poster Presenter: ERIC TOUSSIROT, MD,PhD (he/him/his) – university hospital of BESANCON
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0553: Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness
    Abstract Poster Presenter: Sanjeev Shrestha, MD – Geisinger Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0554: Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
    Abstract Poster Presenter: Maria Luz Garcia Vivar, MD – Basurto Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0555: The Effect of Alcohol Consumption on Clinical Outcomes and Structural Damage in Patients with Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis
    Abstract Poster Presenter: Evelyne Gendron, MD, FRCPC, MSc – University of Toronto, Université Laval
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0556: Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis
    Abstract Poster Presenter: Asier García, MD – Sant Pau Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0557: What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0558: Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
    Abstract Poster Presenter: Maureen Dubreuil, MD, MSc, FACR – Boston University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0559: Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
    Abstract Poster Presenter: Diego Benavent, MD – Hospital Universitari de Bellvitge
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0560: Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides
    Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0561: Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort
    Abstract Poster Presenter: Annie Brink, MS – Lund University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0562: Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study
    Abstract Poster Presenter: Lucia Ondrejčáková, MD – Institute of Rheumatology
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0563: Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort
    Abstract Poster Presenter: Manouk de Hooge, PhD (she/her/hers) – Ghent University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0564: The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
    Abstract Poster Presenter: Joy Feld, MD – Carmel and Zvulun Medical Centre
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0565: Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
    Abstract Poster Presenter: Anthony Lichaa, MPH (he/him/his) – Cliniques universitaires St-Luc
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0566: How Early Is Early? Unveiling Time to Diagnosis Since Symptom Onset and Its Determinants in Patients Suspected of Early Axial Spondyloarthritis: Data from the SPondyloArthritis Caught Early (SPACE) Cohort
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0567: Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
    Abstract Poster Presenter: Pankaj Sharma, PhD – National Institutes of Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0568: Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
    Abstract Poster Presenter: Ameesh Dev, MD – Houston Methodist
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0569: The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort
    Abstract Poster Presenter: Augusta Ortolan, MD PhD – Policlinico Universitario Agostino Gemelli IRCSS
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0570: Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
    Abstract Poster Presenter: Halah Alfatlawi, MD – The University of Toledo
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0571: Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
    Abstract Poster Presenter: SABRINA HAMROUN, MMed – Rheumatology Department, University Hospital of Cochin, Paris
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0572: Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects
    Abstract Poster Presenter: Nigil Haroon, MD, PhD, DM, FRCPC, FRCP, MBA – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0573: Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
    Abstract Poster Presenter: Ansaam Daoud, MD – Case Western Reserve University/University Hospitals
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0574: 14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
    Abstract Poster Presenter: Walter P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0575: Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
    Abstract Poster Presenter: Kurt de Vlam, MD, PhD – Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0576: Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up
    Abstract Poster Presenter: Madeleine Franc, -None- – Université Paris Cité
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0577: AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
    Abstract Poster Presenter: Madeleine Franc, -None- – Université Paris Cité
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0578: Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
    Abstract Poster Presenter: M. Ahmed Saeed, FCPS, MBBS, FRCP, FACP, FACR (he/him/his) – Central Park Medical College
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0579: Association of the Presence of Active Acute Anterior Uveitis with Disease Activity in Axial Spondyloarthritis
    Abstract Poster Presenter: Judith Rademacher, MD (she/her/hers) – Charité Universitätsmedizin Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0580: Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis
    Abstract Poster Presenter: Nigil Haroon, MD, PhD, DM, FRCPC, FRCP, MBA – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0581: Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0582: Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0583: Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0584: Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0585: Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0586: Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0587: Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
    Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0588: Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0589: Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0590: Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0591: Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
    Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0592: Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0593: Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
    Abstract Poster Presenter: Alvin Wells, MD, PhD, FACR – Advocate Aurora Medical Group
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0594: Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
    Abstract Poster Presenter: Jensen Yeung, FRCPC, MD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0595: bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
    Abstract Poster Presenter: Sélina HANNA ABDELMASSIH, MMed – Université Grenoble-Alpes
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0596: Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
    Abstract Poster Presenter: Marina Sánchez, MD – Hospital General Universitario Gregorio Marañón
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0597: Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
    Abstract Poster Presenter: Fabian Proft, MD – Charité Universityhospital Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0598: Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
    Abstract Poster Presenter: Michael T. Nurmohamed, MD, PhD – Amsterdam University Medical Centers & Reade Amsterdam
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0599: Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
    Abstract Poster Presenter: Haseeb Chaudhary, MD – Case Western Reserve University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0600: Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
    Abstract Poster Presenter: Ana-Maria Orbai, MD,MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0601: Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0602: Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
    Abstract Poster Presenter: Alice Gottlieb, MD,PhD – Icahn School of Medicine at Mount Sinai
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0603: Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
    Abstract Poster Presenter: Jakub Závada, MD;PhD – Institute of Rheumatology and Charles University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0604: Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
    Abstract Poster Presenter: Mahum Mirza, DO – Medical College of Wisconsin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0605: Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
    Abstract Poster Presenter: Jenna Parrett, PharmD – Johnson&Johnson Innovative Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    10:30 AM – 12:30 PM Eastern Time
    0606: Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
    Abstract Poster Presenter: Bonit Gill, DO (she/her/hers) – Medical College of Wisconsin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    1:00 PM – 2:30 PM Eastern Time
    16S55: Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I
    Location: Room 147AB
    Abstract Moderator: Sibel Aydin, MD – University of Ottawa - Ottawa
    Abstract Moderator: Proton Rahman, MD – Memorial University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Saturday, Nov 16th
    1:00 PM – 1:15 PM Eastern Time
    0817: 2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults
    Location: Room 147AB
    Presenting Author: Elizabeth Winter, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    1:15 PM – 1:30 PM Eastern Time
    0818: Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
    Location: Room 147AB
    Presenting Author: Stylianos Georgiadis, PhD – Rigshospitalet Glostrup
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    1:30 PM – 1:45 PM Eastern Time
    0819: The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis
    Location: Room 147AB
    Presenting Author: Denis Poddubnyy, MD, PhD, MSc – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    1:45 PM – 2:00 PM Eastern Time
    0820: The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria
    Location: Room 147AB
    Presenting Author: Walter P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    2:00 PM – 2:15 PM Eastern Time
    0821: Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis
    Location: Room 147AB
    Presenting Author: Walter P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    2:15 PM – 2:30 PM Eastern Time
    0822: Investigating the Association Between Alcohol Consumption and Spinal Radiographic Progression in Axial Spondyloarthritis: A Longitudinal Cohort Analysis over a Period of 6 Years
    Location: Room 147AB
    Presenting Author: Evelyne Gendron, MD, FRCPC, MSc – University of Toronto, Université Laval
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Saturday, Nov 16th
    4:30 PM – 5:30 PM Eastern Time
    MTP10A: Meet the Professor: Axial Spondyloarthritis
    Location: Room 148
    Seminar Presenter: Christopher Ritchlin, MD, MPH – Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 1 hours
  • Sunday, Nov 17th
    7:30 AM – 8:30 AM Eastern Time
    MTP10B: Meet the Professor: Axial Spondyloarthritis
    Location: Room 148
    Seminar Presenter: Christopher Ritchlin, MD, MPH – Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 1 hours
  • Sunday, Nov 17th
    9:00 AM – 10:00 AM Eastern Time
    17S08: Sex Differences in Psoriatic Arthritis
    Location: Ballroom A
    Moderator: Courtney J. McCray, MD – University of Texas Health Science Center Houston
    Moderator: Rachael Stovall, MD – University of Washington
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 1 hours
  • Sunday, Nov 17th
    9:00 AM – 9:30 AM Eastern Time
    Sex-Related Differences in Clinical Features and Disease Course in PsA
    Location: Ballroom A
    Speaker: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    9:30 AM – 10:00 AM Eastern Time
    Sex-Related Differences in Treatment Response and Pain Perception in PsA
    Location: Ballroom A
    Speaker: Lihi Eder, MD,PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    SpA Including PsA – Treatment Poster II
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1433: Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients
    Abstract Poster Presenter: Andre Lucas Ribeiro, MD – Universidade Federal do Rio Grande do Sul
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1434: Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio
    Abstract Poster Presenter: Frank Verhoeven, MD,PhD (he/him/his) – CHU Besançon
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1435: Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment
    Abstract Poster Presenter: seong hyeok bak, -None- (he/him/his) – soonchunyang university seoul hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1436: The Association of Cigarette Smoking with Radiographic Progression in Psoriatic Arthritis
    Abstract Poster Presenter: Fadi Kharouf, MD – University Health Network and University of Toronto, Toronto, ON, Canada
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1437: Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
    Abstract Poster Presenter: Sze Lok Lau, BSc, MPH – The Chinese University of Hong Kong
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1438: Performance of Combined MRI SI Joint Active and Structural Lesions in Diagnosing Axial SpA: A Prospective Cohort Study
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1439: Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
    Abstract Poster Presenter: Navya George, MD – Boston University Medical Center Internal Medicine Residency Program
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1440: Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors
    Abstract Poster Presenter: Barry O'Shea, MD – St James's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1441: Factors Associated with the Evolution of Degenerative Spinal Lesions in Axial Spondyloarthritis: 10-Year Follow-up of the DESIR Cohort
    Abstract Poster Presenter: Laura PINA VEGAS, MD, PhD – Rheumatology Department, Leiden University Medical Centre (LUMC)
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1442: Relationship Between Degenerative Lesions over Time in Axial Spondyloarthritis: 10-year Follow-up of the DESIR Cohort
    Abstract Poster Presenter: Laura PINA VEGAS, MD, PhD – Rheumatology Department, Leiden University Medical Centre (LUMC)
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1443: Natural Course of Degenerative Lesions of the Spine on Radiographs and MRI in Axial SpondyloarthritisFollowed 10 Years in the DESIR Cohort
    Abstract Poster Presenter: Laura PINA VEGAS, MD, PhD – Rheumatology Department, Leiden University Medical Centre (LUMC)
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1444: Characterization and Comparison of MRI Findings in Axial Spondyloarthritis, Axial Psoriatic and Chronic Non-inflammatory Back Pain
    Abstract Poster Presenter: Mauricio Parada, n/a (he/him/his) – Hospital Clínico Universidad de Chile
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1445: Systematic Characterization of MRI Lesions Per ASAS Definitions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Comparisons Among Subgroups with Psoriasis, Iritis, Colitis, AxSpA Alone, and Matched Back Pain Controls
    Abstract Poster Presenter: Ulrich Weber, MD – Practice Zenit Schaffhausen
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1446: Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?
    Abstract Poster Presenter: Servet Yüce, n/a – Şırnak Provincial Health Directorate Public Health Department
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1447: The Frequency of Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Spondyloarthritis in Comparison to Age and Sex-matched Controls and Impact of SpA on Onset Age of DISH
    Abstract Poster Presenter: Ummugulsum Gazel, MD – University of Ottawa
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1448: The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting
    Abstract Poster Presenter: Emmanuel Katsaros, DO (he/him/his) – Western University of Health Sciences
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1449: Evaluating Spine Structural Damage on a Single CT in Patients with Ankylosing Spondylitis, and According to the Presence of Skin Psoriasis
    Abstract Poster Presenter: Andrea MENNINI, MD – NANCY
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1450: Radiographic Structural Spine Assessment in Ankylosing Spondylitis According to the Presence or Absence of Psoriasis
    Abstract Poster Presenter: Inès FAVRE-FELIX, -None- – Nancy university
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1451: Predictors and Patterns of Fragility Fracture in an Observational Cohort of Patients with Psoriatic Arthritis
    Abstract Poster Presenter: Marwan Bukhari, PhD, FRCP – University Hospitals of Morecambe bay NHS foundation trust
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1452: Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
    Abstract Poster Presenter: Pamela Weiss, MD – Childrens Hospital of Philadelphia
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1453: Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study
    Abstract Poster Presenter: Li Guo, PhD – Kanova biopharma
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1454: Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
    Abstract Poster Presenter: Andrew Concoff, MD – Exagen, Inc.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1455: Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
    Abstract Poster Presenter: Fadi Kharouf, MD – University Health Network and University of Toronto, Toronto, ON, Canada
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1456: Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1457: Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care - 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
    Abstract Poster Presenter: Marinus Vis, MD – Erasmus MC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1458: Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients
    Abstract Poster Presenter: Pauline KRUG, MD (she/her/hers) – Cliniques universitaires St-Luc
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1459: Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity
    Abstract Poster Presenter: Michael Nissen, MBBS,FRACP – Geneva University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1460: Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
    Abstract Poster Presenter: Lou Kawka, n/a (she/her/hers) – Hôpital Universitaire de Strasbourg
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1461: Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center
    Abstract Poster Presenter: Lourdes Martín de la Sierra López, BA – HGUCR
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1462: Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
    Abstract Poster Presenter: Pavithra Srinivas, PharmD, BCIDP – Janssen Scientific Affairs LLC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1463: Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
    Abstract Poster Presenter: Sue Cheng, MD – Amgen Inc.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1464: Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
    Abstract Poster Presenter: mitsumasa kishimoto, MD – Kyorin University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1465: The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1466: Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks - Data from a Phase 4 Trial
    Abstract Poster Presenter: Laure Gossec, MD, PhD – Sorbonne Universite
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1467: Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials
    Abstract Poster Presenter: Kristi Mizelle, MD – TPMG Rheumatology
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1468: Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials
    Abstract Poster Presenter: Diego Benavent, MD – Hospital Universitari de Bellvitge
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1469: Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
    Abstract Poster Presenter: Rocio Gonzalez Molina, PhD (she/her/hers) – Hospital Reina Sofía
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1470: Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1471: Sex-related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-analysis
    Abstract Poster Presenter: Lihi Eder, MD,PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1472: Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
    Abstract Poster Presenter: Anthony Todd, PharmD – Johnson & Johnson
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1473: Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
    Abstract Poster Presenter: M. Elaine Husni, MD;MPH – Cleveland Clinic
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1474: Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Abstract Poster Presenter: Oyediran Adelakun, MPH – Janssen Research & Development, LLC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1475: Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1476: Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
    Abstract Poster Presenter: Mark Hwang, MD;MS – Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1477: Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
    Abstract Poster Presenter: Alice Gottlieb, MD, PhD – Icahn School of Medicine at Mount Sinai
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1478: Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
    Abstract Poster Presenter: Enrique Soriano, MD, MSc – Hospital Italiano de Buenos Aires
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1479: Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study
    Abstract Poster Presenter: Philipp Sewerin, MD,PhD – Ruhr-University Bochum, Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1480: Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1481: Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    10:30 AM – 12:30 PM Eastern Time
    1482: Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    11:30 AM – 12:30 PM Eastern Time
    MTP14A: Meet the Professor: Psoriatic Arthritis
    Location: Room 153
    Seminar Presenter: Arthur Kavanaugh, MD – UCSD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 1 hours
  • Sunday, Nov 17th
    1:00 PM – 2:00 PM Eastern Time
    17S25: Approach to Difficult-to-Manage Spondyloarthritis
    Location: Hall D/E
    Moderator: Mark Hwang, MD;MS – Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston
    Moderator: Rebecca Haberman, MD – NYU Langone Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 1 hours
  • Sunday, Nov 17th
    1:00 PM – 1:30 PM Eastern Time
    Therapy Selection in Difficult to Manage Spondyloarthritis
    Location: Hall D/E
    Speaker: Dennis McGonagle, MD,PhD – Uni of Leeds
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    1:30 PM – 2:00 PM Eastern Time
    Chronic Pain in Spondyloarthritis: Differentiating Active Disease From Fibromyalgia
    Location: Hall D/E
    Speaker: Liron Caplan, MD;PhD – Rocky Mountain Regional VAMC
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:00 PM – 4:30 PM Eastern Time
    17S67: Abstracts: SpA Including PsA – Basic Science
    Location: Room 150AB
    Abstract Moderator: Christopher Ritchlin, MD, MPH – Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School
    Abstract Moderator: Monica Guma, MD,PhD – UCSD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Sunday, Nov 17th
    3:00 PM – 4:30 PM Eastern Time
    17S68: Abstracts: SpA Including PsA – Treatment I
    Location: Ballroom B
    Abstract Moderator: Abin Puravath, MD,FACP,MHS – Cedars-Sinai
    Abstract Moderator: Joerg Ermann, MD – Brigham and Women's Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Sunday, Nov 17th
    3:00 PM – 3:15 PM Eastern Time
    1707: TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
    Location: Room 150AB
    Presenting Author: Stephanie Glavaris, PhD – The Johns Hopkins University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:00 PM – 3:15 PM Eastern Time
    1755: Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis
    Location: Ballroom B
    Presenting Author: Michael Paley, MD, PhD – Washington University in St. Louis
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:15 PM – 3:30 PM Eastern Time
    1708: Unveiling the Uterine-Joint Axis: Dysbiosis and Subclinical Uterine Inflammation in Female Axial Spondyloarthritis Pathogenesis
    Location: Room 150AB
    Presenting Author: Daniele Mauro, MD,PhD – University of Campania, Italy
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:15 PM – 3:30 PM Eastern Time
    1756: What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
    Location: Ballroom B
    Presenting Author: Jette Heberg, MSc – Copenhagen Center for Arthritis Research, COPECARE
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:30 PM – 3:45 PM Eastern Time
    1709: Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis
    Location: Room 150AB
    Presenting Author: Steven Dang, BSc – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:30 PM – 3:45 PM Eastern Time
    1757: Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
    Location: Ballroom B
    Presenting Author: Walter P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:45 PM – 4:00 PM Eastern Time
    1710: Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA
    Location: Room 150AB
    Presenting Author: Stéphane Hilliquin, MD – UNIVERSITE PARIS CITE
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    3:45 PM – 4:00 PM Eastern Time
    1758: Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
    Location: Ballroom B
    Presenting Author: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    4:00 PM – 4:15 PM Eastern Time
    1711: Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
    Location: Room 150AB
    Presenting Author: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    4:00 PM – 4:15 PM Eastern Time
    1759: Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
    Location: Ballroom B
    Presenting Author: Denis Poddubnyy, MD, PhD, MSc – University Health Network
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    4:15 PM – 4:30 PM Eastern Time
    1712: Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment
    Location: Room 150AB
    Presenting Author: Jiangnan Xie, -None- – Fudan University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    4:15 PM – 4:30 PM Eastern Time
    1760: A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
    Location: Ballroom B
    Presenting Author: Walter P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Sunday, Nov 17th
    4:30 PM – 5:30 PM Eastern Time
    MTP14B: Meet the Professor: Psoriatic Arthritis
    Location: Room 153
    Seminar Presenter: Arthur Kavanaugh, MD – UCSD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 1 hours
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    SpA Including PsA – Treatment Poster III
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2311: Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans
    Abstract Poster Presenter: Natalie Anumolu, MD – Medical College of Wisconsin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2312: National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
    Abstract Poster Presenter: Dilli Poudel, MD (he/him/his) – Vanderbilt University, Nashville, TN
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2313: Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
    Abstract Poster Presenter: Christine Loftis, MD (she/her/hers) – University of Colorado Anschutz School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2314: Serum Calprotectin (S100A8/9) and Complement Factor C3 as Potential Inflammatory Markers in Obese and “CRP Negative” Early PsA Patients: Data from a Multicenter METAPSA Cohort
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2315: Exploring Antibodies in Psoriatic Arthritis: A Novel Autoimmune Biomarker Discovered
    Abstract Poster Presenter: Théo WIRTH, MD (he/him/his) – AP-HM
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2316: Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
    Abstract Poster Presenter: Pauline KRUG, MD (she/her/hers) – Cliniques universitaires St-Luc
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2317: Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study
    Abstract Poster Presenter: Fadi Kharouf, MD – University Health Network and University of Toronto, Toronto, ON, Canada
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2318: Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
    Abstract Poster Presenter: Fadi Kharouf, MD – University Health Network and University of Toronto, Toronto, ON, Canada
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2319: Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns
    Abstract Poster Presenter: Sheng Han Li, MSc – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2320: Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
    Abstract Poster Presenter: LUIS EDUARDO BRIONES GARCÍA, MD – Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2321: Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
    Abstract Poster Presenter: Nahia Plaza-Aulestia, MD – Rheumatology division. Galdakao-Usansolo University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2322: Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
    Abstract Poster Presenter: Gary Macfarlane, MD,PhD,BSc,MBChB,DSc – University of Aberdeen
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2323: The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis
    Abstract Poster Presenter: Keith Colaco, MSc – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2324: Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients with and Without First-degree Relatives with Psoriatic Disease
    Abstract Poster Presenter: Catherine Howe, MD – NYU
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2325: Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
    Abstract Poster Presenter: Stylianos Georgiadis, PhD – Rigshospitalet Glostrup
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2326: Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
    Abstract Poster Presenter: Douglas White, MD, PhD – Aspirus
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2327: Differential Quantitative Profile of Myeloid Derived Suppressor Cells and Monocyte Subsets Relate to Clinical Phenotype and Disease Activity in Psoriatic Arthritis Patients
    Abstract Poster Presenter: Jennifer Tiaré Balderas Miranda, -None- – Universidad Nacional Autónoma de México
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2328: Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
    Abstract Poster Presenter: Virginia Carrizo Abarza, Sr, MD (she/her/hers) – Toronto Western Hospital - University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2329: Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
    Abstract Poster Presenter: Sarah Romanelli, BS – Icahn Mount Sinai School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2330: Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
    Abstract Poster Presenter: Rebecca Haberman, MD – NYU Langone Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2331: Assessment of the Likelihood of Joint Inflammation Recurrence in Previously Affected Joints During Psoriatic Arthritis Disease Course
    Abstract Poster Presenter: Mark Berman, MD (he/him/his) – Tel Aviv Sourasky Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2332: PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
    Abstract Poster Presenter: Clementina Lopez-Medina, MD – Reina Sofia University Hospital
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2333: Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells
    Abstract Poster Presenter: Jesús Eduardo Martín Salazar, MSc (he/him/his) – University of Córdoba
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2334: Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
    Abstract Poster Presenter: Murat Torgutalp, MSc (he/him/his) – Charité Universitätsmedizin - Berlin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2335: Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study
    Abstract Poster Presenter: Birte Coppers, MSc (she/her/hers) – University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2336: Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2337: Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
    Abstract Poster Presenter: Namrata Singh, MD,MSc – University of Washington
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2338: TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
    Abstract Poster Presenter: Lenche Kostadinova, MD – Louis Stokes VA Medical Center/CWRU
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2339: Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study
    Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2340: Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
    Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2341: Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
    Abstract Poster Presenter: Lihi Eder, MD,PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2342: Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Abstract Poster Presenter: Lihi Eder, MD,PhD – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2343: Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD
    Abstract Poster Presenter: Adam Mayer, MD (he/him/his) – University of Pennsylvania/Children's Hospital of Philadelphia
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2344: Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
    Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2345: Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
    Abstract Poster Presenter: Andre Lucas Ribeiro, MD – Universidade Federal do Rio Grande do Sul
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2346: Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
    Abstract Poster Presenter: Anthony Lichaa, MPH (he/him/his) – Cliniques universitaires St-Luc
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2347: Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
    Abstract Poster Presenter: Thao Pham, MD, PhD – Assistance Publique-Hôpitaux de Marseille
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2348: Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
    Abstract Poster Presenter: Joseph Merola, MD;MSc;FACR;FAAD – UT Southwestern Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2349: Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
    Abstract Poster Presenter: Sheng Han Li, MSc – University of Toronto
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2350: Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
    Abstract Poster Presenter: Stylianos Georgiadis, PhD – Rigshospitalet Glostrup
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2351: Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
    Abstract Poster Presenter: Irene van der Horst-Bruinsma, MD, PhD – Radboud umc
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2352: Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2353: Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
    Abstract Poster Presenter: Toby Thomas, PharmD – Johnson & Johnson
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2354: Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
    Abstract Poster Presenter: Alan Kivitz, MD,MACR – Altoona Center for Clinical Research
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2355: Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
    Abstract Poster Presenter: Laure Gossec, MD, PhD – Sorbonne Universite
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2356: Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2357: Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
    Abstract Poster Presenter: Ryan Funk, PhD, PharmD – Johnson & Johnson Innovative Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2358: Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis
    Abstract Poster Presenter: Jaejoon Lee, MD, PhD – Samsung Medical Center
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2359: A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2360: Patient Selection and Treatment Outcomes Using Preliminary Data-driven Definition versus the Established ASAS Definition of a Positive MRI of the Sacroiliac Joint in axSpA: Post-hoc Analysis from COAST-X
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2361: Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
    Abstract Poster Presenter: Arthur Kavanaugh, MD – UCSD
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2362: Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
    Abstract Poster Presenter: Mindy Kim, PharmD – UCB, Inc.
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2363: “How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2364: Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
    Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2365: Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2366: Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2367: Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2368: Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    10:30 AM – 12:30 PM Eastern Time
    2369: Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    1:00 PM – 2:30 PM Eastern Time
    18M60: Abstracts: SpA Including PsA – Treatment II
    Location: Ballroom B
    Abstract Moderator: Alexis Ogdie, MD – University of Pennsylvania
    Abstract Moderator: Jose Scher, MD – New York University School of Medicine
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Monday, Nov 18th
    1:00 PM – 1:15 PM Eastern Time
    2581: Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
    Location: Ballroom B
    Presenting Author: Yu Xue, MD,PhD – Huashan Hospital affiliated to Fudan University
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    1:15 PM – 1:30 PM Eastern Time
    2582: Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Location: Ballroom B
    Presenting Author: Iain McInnes, PhD, FRCP – University of Glasgow
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    1:30 PM – 1:45 PM Eastern Time
    2583: Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study
    Location: Ballroom B
    Presenting Author: Mikkel Østergaard, MD, PhD, DMSc – Rigshospitalet, University of Copenhagen
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    1:45 PM – 2:00 PM Eastern Time
    2584: Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
    Location: Ballroom B
    Presenting Author: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    2:00 PM – 2:15 PM Eastern Time
    2585: Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
    Location: Ballroom B
    Presenting Author: Laure Gossec, MD, PhD – Sorbonne Universite
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    2:15 PM – 2:30 PM Eastern Time
    2586: Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
    Location: Ballroom B
    Presenting Author: Andreas Ramming, MD (he/him/his) – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    3:00 PM – 4:30 PM Eastern Time
    18M69: Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II
    Location: Room 146AB
    Abstract Moderator: Paras Karmacharya, MD, MS – Vanderbilt University, Nashville, TN
    Abstract Moderator: Sherry Rohekar, MD, FRCPC – University of Western Ontario - London
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
     CME 0 hours
  • Monday, Nov 18th
    3:00 PM – 3:15 PM Eastern Time
    2635: Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Appropriateness of Rheumatology Referrals and Treatment Outcomes
    Location: Room 146AB
    Presenting Author: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    3:15 PM – 3:30 PM Eastern Time
    2636: Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
    Location: Room 146AB
    Presenting Author: Stephen PENNINGTON, PhD (he/him/his) – University College Dublin
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    3:30 PM – 3:45 PM Eastern Time
    2637: Chaperone-mediated Autophagy in Synovitis Distinguishes Psoriatic Arthritis from Rheumatoid Arthritis
    Location: Room 146AB
    Presenting Author: Florenzo Iannone, MD;PhD – Rheumatology Unit- University of Bari "Aldo Moro", IT
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    3:45 PM – 4:00 PM Eastern Time
    2638: Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level
    Location: Room 146AB
    Presenting Author: Andre Lucas Ribeiro, MD – Universidade Federal do Rio Grande do Sul
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    4:00 PM – 4:15 PM Eastern Time
    2639: Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs
    Location: Room 146AB
    Presenting Author: Fadi Kharouf, MD – University Health Network and University of Toronto, Toronto, ON, Canada
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
  • Monday, Nov 18th
    4:15 PM – 4:30 PM Eastern Time
    2640: Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
    Location: Room 146AB
    Presenting Author: Alexander Wu, BS – University of Texas Southwestern Medical School
    Spondyloarthritis (SpA) including psoriatic arthritis (PsA)